Introduction {#Sec1}
============

Preoperative radiotherapy (RT) alone or in combination with chemotherapy (CT), is the standard treatment in patients with extra-peritoneal locally advanced rectal cancer (LARC). In patients with unresectable or resectable disease, where "downsizing" and "downstaging" are required (cT3--4 mesorectal fascia \[MRF\] +/N0--2 or cT3 MRF −/+ N0 of the lower rectum) combination therapy is recommended \[[@CR1]\]. Although this multimodality approach leads to an improvement in local control as well as in a significantly higher rates of complete pathological response (pCR), ranging from 13% to 20%, 25--30% of these patients will experience metastatic disease \[[@CR1]\]. The evidence that pCR after preoperative chemoradiotherapy (CT-RT) represents an independent favourable prognostic factor for local control, overall survival (OS) and disease free survival (DFS) \[[@CR2]\], led to evaluate the role of CT-RT intensification. Treatment intensification with the concurrent CT was evaluated in five randomized trials adding Oxaliplatin to either 5FU or Capecitabine \[[@CR3]--[@CR7]\]. Only one of these studies demonstrated improved outcomes, whereas all studies reported a significantly increased toxicity \[[@CR4]\]. Conversely, the evidence of a dose-response relationship in terms of local control and tumor regression grade for RT doses \> 50--60 Gy \[[@CR8], [@CR9]\] as well as radiobiological data \[[@CR10]\] provide a strong rationale for intensified RT with the delivery of higher doses in a shorter time. The favourable results reported by a number of phase I-II studies, evaluating the role of RT intensification with several accelerated fractionation schedules combined with 5FU-based CT in LARC, support these observations \[[@CR11], [@CR12]\]. More recently, a phase III randomized trial (INTERACT Trial), which compared radiation dose intensification with 3D conformal RT (3D--CRT) using a concomitant boost technique and Capecitabine versus standard RT and CT intensification by adding Oxaliplatin to Capecitabine, showed no difference in terms of pCR, local control and survival. Conversely, the study reported a statistically significant difference in terms of compliance and acute toxicity in favour of the intensified RT arm \[[@CR13]\].

In order to evaluate the role of RT intensification, a number of phase II studies with preoperative intensity-modulated RT (IMRT) have documented the benefit in terms of feasibility and toxicity of simultaneous integrated boost (SIB) intensification in combination with fluoropyrimidine-based CT in patients with LARC. Favourable short and long-term results were reported \[[@CR14]--[@CR16]\]. Accordingly, in this pooled analysis we aimed to retrospectively analyze the data of LARC patients treated with intensified preoperative RT (IMRT-SIB) and Capecitabine in terms of feasibility, toxicity and efficacy.

Materials and methods {#Sec2}
=====================

Inclusion criteria {#Sec3}
------------------

Patients from five Italian radiation oncology centers with a histological diagnosis of extra-peritoneal LARC (stage II-III), were included in the study.

Information regarding clinical history, physical examination, digital rectal examination, CEA determination, blood profile, and staging exams including colonscopy with biopsy, chest and abdomen CT-scan, endoscopic ultrasound and pelvic MRI were gathered. In particular the MRF involvement was assessed according to the MERCURY study group criteria \[[@CR17]\].

IMRT was delivered to the entire mesorectum and obturator, presacral, internal iliac lymph nodes (plus external iliac lymph nodes in the cT4 patients) (CTV1) with SIB to the tumour and corresponding mesorectum plus an MRI-based cranio-caudal extension of 1--2 cm (CTV2). Concomitant Capecitabine was administered. Organs at risk constraints and prescribed dose as well as surgical and pathological details after operation, including the standardized five-points tumour regression grade (TRG) according to Mandard et al. \[[@CR18]\] had to be available. A pCR was defined as no visible microscopic disease in the primary tumour and lymph-nodes. All patients enrolled in the analysis had to report at least one month of follow-up after surgery. The study was approved by the Internal Review Boards of the participating centers.

Objectives of the study {#Sec4}
-----------------------

Our purpose was to determine the feasibility, efficacy and toxicity of RT intensification with IMRT-SIB and concomitant Capecitabine. The feasibility was assessed on the basis of compliance with the proposed treatment, by evaluating RT and concomitant CT separately. Efficacy was defined by tumour and nodal down-staging and TRG according to the Mandard score \[[@CR18]\]. Acute toxicity was evaluated according to the CTC-AE 4.0 scale. Post-operative morbidity was evaluated after 30 days from surgery.

Statistical analysis {#Sec5}
--------------------

The Chi-square test was used to compare data of tumor response (downstaging) between different IMRT-SIB doses given (52.5Gy vs 54Gy vs 55Gy vs 57.5Gy). Odds ratio (OR) and 95% confidence interval (CI) for TRG1(pCR) and downstaging were calculated using logistic regression model, adjusting for sex, age, distance of the lower tumor pole from external anal sphyncther (EAS), clinical tumor stage (cT), clinical nodal stage (cN), MRF involvement and RT dose intensity levels, when appropriate.

Results {#Sec6}
=======

Patient population {#Sec7}
------------------

From October 2013 to May 2016, 76 patients were included in the analysis. The majority of patients (97.4%) were in good general condition (ECOG 0--1), without significant co-morbidities. In 63 out of 76 patients (83%) tumour localization was in the lower rectum (≤ 6 cm from EAS), and in 71% the tumor was defined as a tethered mass at digital rectal examination. Most cases were stage IIIB (64.5%) and MRF involvement was documented in 45% of patients. Patient, tumor characteristics and RT doses are reported in Table [1](#Tab1){ref-type="table"}.Table 1Patient and tumor characteristicsn *(%)*Sex Male50 (*65.8)* Female*26 (34.2)*Median age *(range)*64 yrs. *(29--84)*Performance status  *ECOG 0--1*74 *(97.4)*  *ECOG 2*2 *(2.6)*Median tumor size *(range)*50 mm *(25--120)*Median tumor distance-EAS *(range)*60 mm *(10--120)*Tumor Stage cT25 *(6.5)* cT363 *(82.9)* cT48 *(10.6)*cN cN012 *(15.8)* cN139 *(51.3)* cN225 *(32.9)*Stage IIA12 *(15.8)* IIIA3 *(3.9)* IIIB49 *(64.5)* IIIC12 *(15.8)*MRF involvement Yes34 *(44.7)* No42 *(55.3)*IMRT-SIB dose (dose per fraction)52.5 Gy (2.1Gy)16 *(21)*54 Gy (2.16Gy)24 *(31.5)*55 Gy (2.2Gy)34 *(45)*57.5 Gy (2.5Gy)2 *(2.5)MRF* Mesorectal fascia

Treatment compliance and acute toxicity {#Sec8}
---------------------------------------

All patients received a prescription of 45 Gy in 25 fractions to the CTV1. The dose to CTV-SIB (CTV2) ranged from 52.5Gy, 2.1Gy/fraction (16 patients), 54Gy, 2.16Gy/fraction (24 patients), 55Gy, 2.2Gy/fraction (34 patients) to 57.5 Gy, 2.3Gy/fraction (2 patients) corresponding to an equivalent dose at 2 Gy/fraction (EQD2) of 53.24, 55.22Gy, 56.55Gy, to 59.94Gy respectively, (considering α/β = 5.06 Gy for rectal tumor \[[@CR16]\]). The median dose was 54 Gy (EQD2: 55.22 Gy). The CTV-SIB dose was a choice of the cancer center; all patients were treated equally at their respective centers. Preoperative IMRT-SIB was given with "step and shoot", "sliding window", VMAT and Tomotherapy techniques in 24%, 28%, 44% and 4% of patients, respectively. Overall, 74 out of 76 (97.4%) patients completed IMRT-SIB as planned. Capecitabine at a dose of 1650 mg/m2/daily for the entire course of the RT was administered in 64 of 76 (84.2%) patients. The remaining 12 patients interrupted CT due to haematological (4), gastrointestinal toxicity (3) or other causes (5). Therefore compliance to IMRT-SIB and concurrent Capecitabine was 97.4% and 84.2%, respectively.

Major G3--4 toxicity was reported in 8 patients (10.5%). Gastrointestinal and haematological toxicities were the most commonly reported. There were no treatment related deaths. Toxicity details are reported in Table [2](#Tab2){ref-type="table"}.Table 2Acute toxicityToxicityG1-G2, n *(%)*G3-G4, n *(%)*GI29 *(38.1)*5 *(6.6)*GU23 *(30.3)*0 *(0)*Haematological14 *(18.4)*2 *(2.6)*Skin9 *(11.8)*0 *(0)*Cardiac3 *(3.9)*1 *(1.3)GI* Gastrointestinal, *GU* Genitourinary

Response to treatment and surgical data {#Sec9}
---------------------------------------

Overall, 72 out of 76 (94.7%) patients underwent surgery consisting of low anterior resection (LAR) in 53 (73.6%), abdomino-perineal resection (APR) in 11 (15.3%) and trans-anal local excision (LE) in 8 (11.1%) patients, respectively. Among the remaining four patients, three with lower rectum cancer and complete clinical response at post-CT-RT re-staging refused surgery and one patient showed a systemic progression of disease after CT-RT. Postoperative complications at 30 days after operation were reported in 13 (18%) patients. In particular, 3 (4.2%) patients underwent surgery for small-bowel obstruction, anastomotic leakage and pelvic abscess, respectively. Further details are reported in Table [3](#Tab3){ref-type="table"}. The median time from the end of the CT-RT to surgery was 10.7 weeks (range 6.4--12.4 weeks).Table 3Postoperative complicationsSurgery (n. of patients)Anastomotic leakageBleedingPelvic abscessSmall-bowel obstructionOthersTotal, n *(%)*LAR (53/72)1232311 *(15.3)*APR (11/72)001012 *(2.8)*LE (8/72)000000 *(0)*Total, n *(%)*1 *(1.4)*2 *(2.8)*4 *(5.6)*2 *(2.8)*4 *(5.6)*13 *(18.1)*

Tumour and lymph node downstaging was documented in 51 (70.8%) of 72 operated patients, including LE, and in 43 (67%) of 64 radically operated patients, respectively. Overall, 46 (63.9%) patients achieved a major pathologic response (TRG1--2). In particular the tumor pCR (pT0) was documented in 20 (27.8%) out of 72 patients and 14 (22%) out of 64 radically operated patients achieved a pCR (pT0N0). Response to treatment is reported in Table [4](#Tab4){ref-type="table"}. Circumferential resection margin (CRM) was positive in 3 (4%) out of the 72 surgically treated patients. The 3 patients account for 9% of the 34 with MRF involvement.Table 4Response to treatment: T/N down-staging and TRGpT0pT1pT2pT3pT4Total, n *(%)*cT2201003 *(4.2)*cT31781719061 *(84.7)*cT4102418 *(11.1)*Total, n *(%)*20 *(27.8)*8 *(11.1)*20 *(27.8)*23 *(31.9)*1 *(1.4)*72 *(100)*pN0pN1pN2pNx^a^Total, n *(%)*cN0721212 *(16.7)*cN12291537 *(51.4)*cN21921123 *(31.9)*Total, n *(%)*48 *(66.7)*13 *(18.1)*3 *(4.2)*8 *(11.1)*72 *(100)*TRG1TRG2TRG3TRG4TRG5Total, n *(%)*cT2210003 *(4.2)*cT31721212061 *(84.7)*cT4143008 *(11.1)*Total, n *(%)*20 *(27.8)*26 *(36.1)*24 *(33.3)*2 *(2.8)*0 *(0)*72 *(100)*^a^Patient underwent local excision

Adjuvant chemotherapy was planned in patients with pathologic positive lymph nodes by all participating centers. Overall, 16 (22%) out 72 patients received adjuvant chemotherapy with Capecitabine 2000 mg/m2/daily for 14 days, q 3 weeks. Capecitabine was given according to the planned time and dose to all 16 patients.

The potential impact of some patient and tumor characteristics and of the different IMRT-SIB dose levels on TRG1 (pT0) and tumor downstaging were evaluated by both univariate and multivariate analyses. No difference for any of the considered prognostic factors was reported, except for the distance of lower pole of tumor from EAS ≥ 60 mm (OR = 0.12). Also, no difference was reported for the IMRT-SIB dose levels when compared by chi-square test (*p* = 0.47) and evaluated by the multivariate analysis (Table [5](#Tab5){ref-type="table"}).Table 5Odds ratios (OR) and corresponding 95% confidence intervals (CI) for TRG1 and tumor downstaging according to selected characteristicsTRG 1OR (95% CI)^a^DownstagingOR (95% CI)^a^n(%)n(%)Sex Man13(26.0)Reference34(70.8)Reference Woman7(26.9)1.67 (0.60--4.62)18(72.0)0.90 (0.21--3.88)Age (years) \< 555(29.4)Reference12(70.6)Reference 55--645(18.5)0.36 (0.10--1.27)14(56.0)0.37 (0.07--1.99) 65--746(31.6)1.01 (0.26--3.85)16(84.2)2.93 (0.40--21.37) ≥ 754(30.8)0.85 (0.20--3.56)10(83.3)2.75 (0.34--22.48)Distance EAS (mm) \< 609(23.7)Reference29(80.6)Reference ≥ 608(27.6)0.88 (0.30--2.55)17(58.6)0.12 (0.02--0.69) Unknown3(33.3)1.026 (0.22--7.12)6(75.0)0.15 (0.01--2.43)cT cT22(40.0)Reference3(100.0)- cT317(27.0)0.29 (0.02--4.14)42(67.7)- cT41(12.5)0.29 (0.02--5.68)7(87.5)-cN cN04(33.3)Reference8(66.7)Reference cN110(25.6)0.59 (0.16--2.23)25(67.6)0.39 (0.06--2.60) cN26(24.0)0.77 (0.18--3.34)19(79.2)1.14 (0.17--7.82)MRF involvment No6(17.7)Reference31(79.5)Reference Yes14(33.3)0.34 (0.11--1.01)21(61.8)0.29 (0.07--1.18)Single dose intensity 2.13(18.8)Reference12(80.0)Reference 2.169(37.5)1.45 (0.36--5.84)15(62.5)0.16 (0.02--1.47) ≥ 2.28(22.2)1.45 (0.39--5.38)25(73.5)1.14 (0.14--9.25)^a^Adjusted for all variables reported in the table

Discussion {#Sec10}
==========

Given the reported relationship between RT-delivered dose and tumor response, RT intensification represents an attractive possibility to improve the clinical outcome in LARC. The recent results from the phase III INTERACT trial demonstrating an equivalent efficacy, with better compliance and tolerance of RT intensification using 3D--CRT concomitant boost with Capecitabine-based CT compared with CT intensification with Capecitabine plus Oxaliplatin and standard RT, prompted our interest to investigate treatment optimization programs in RT intensification with IMRT for LARC \[[@CR13], [@CR19]--[@CR23]\].

In our experience on 76 LARC patients~~,~~ the treatment appeared to be feasible and effective. IMRT-SIB with a dose range of 52.5--57.5Gy (median 54Gy) and Capecitabine with 1650 mg/m^2^/daily resulted in a low rate of toxicity; grade ≥ 3 gastrointestinal (GI) and overall grade ≥ 3 toxicity was reported in only 6.6% and 10.5% patients, respectively. These data appear closely comparable with the other available IMRT-SIB intensification and Capecitabine phase II studies or retrospective series \[[@CR24]--[@CR29]\]. These studies documented grade ≥ 3 acute toxicity rates of 4--25% with a dose range of 47.5--57.5Gy (median 55Gy); therefore our results confirm the optimal tolerance of this treatment intensification modality. Interestingly, a higher incidence with 25% of major toxicity was reported by Arbea et al. \[[@CR29]\] when Oxaliplatin was added to Capecitabine, requiring RT dose attenuation (from 2.5Gy to 2.4Gy/fraction), thus suggesting the potential limitations in feasibility of IMRT-SIB with multidrug chemotherapy. The 6.6% rate of grade ≥ 3 GI acute toxicity is significantly lower than the 12.6%--20% rate of the preoperative CT-RT with two-drug CT arm (5FU or Capecitabine plus Oxaliplatin and 3D--CRT of 50.4Gy), whereas is similar to the 3.2%--15% rate of the preoperative standard CT-RT arm (5FU or Capecitabine alone with 3D--CRT of 50.4Gy), which were reported in the more recent randomised trials \[[@CR3]--[@CR7]\]. This favourable toxicity rate is also lower than the 24% rate reported by Myerson et al. \[[@CR11]\] and the 15% rate more recently reported by Valentini et al. \[[@CR13]\] with RT intensification using 3D--CRT concomitant boost technique and Capecitabine. This remarkable difference could be mainly attributed to a significantly decreased incidence of diarrhea as a result of improved small bowel sparing with IMRT-SIB technique as reported by Samuelian et al. \[[@CR30]\] in their retrospective study comparing IMRT to the more conventional 3D--CRT.

The good tolerance to IMRT-SIB allowed a treatment compliance as high as 97.4% for the RT and 84.2% for the CT component, which is well comparable to 93.6% and 91% rates reported with 3D--CRT concomitant boost technique and Capecitabine, respectively (13). These results are consistent with the other published studies with CT-RT intensification using IMRT-SIB, which confirm the feasibility of this treatment approach (Table [6](#Tab6){ref-type="table"}). Overall, in our experience, the compliance of IMRT-SIB and Capecitabine was closely comparable also to the standard 3D--CRT and 5FU or Capecitabine of the control arm (92--100% for RT and 79--97% for CT) reported in the more recent randomized trials \[[@CR3]--[@CR7]\]. In addition, IMRT dose intensification did not adversely affect the compliance to adjuvant chemotherapy, which was 100% for the 16 patients treated after surgery.Table 6Short-term results of phase II and of retrospective available studiesAuthor\
*(* ^*a*^ *Study)*N. of patientsStageRadiotherapyCompliance RT-CTpCRTox ≥ 3Post-op morbidityDe Ridder et al. \[[@CR24]\]\
*(Phase II)*24/13T3-T4\
MRF+46Gy/23fr/2\
*SIB* 55.2Gy/23fr/2.4Gyfr100% -noCT14%4.2%8%Li et al. \[[@CR25]\]\
*(Phase II)*63T3-T4\
N+41.8Gy/22fr/1.9\
*SIB* 50.6Gy/22fr/2.3Gyfr100% --100%31%14%7%Hernando et al. \[[@CR26]\]\
*(Retrospective)*74T2-T4\
N+45Gy/25fr/1.8\
*SIB* 57.5Gy/25fr/2.3Gyfr99% -- 99%31%17.6%7%Zhu et al. \[[@CR27]\]\
*(Phase II)*78T3-T4\
N0/N+50Gy/25fr/2\
*SIB* 55Gy/25fr/2.2Gyfr100% -- 62%24%14%17%Wang et al. \[[@CR28]\]\
*(Retrospective)*260T3-T4-\
N0/N+41.8Gy/22fr/1.9\
*SIB* 50.6Gy/22fr/2.3Gyfr99% -- 99%18.5%6%23%^b^Arbea et al. \[[@CR29]\]\
*(Phase II)*100T3-T4\
N+47.5Gy/19fr/2.5 *and*\
47.5Gy/20fr/2.4Gyfr97% -- 80%13%25%7%Our experience76T3-T4\
N0/N+45 Gy/25fr/1.8\
*SIB* 52.5--57.Gy/25fr 2.1--2.3Gyfr97.4% -- 84%22%10.5%18%^a^All Studies included concurrent Capecitabine ^b^Concurrent Capecitabine-Oxaliplatin

Data related to treatment response were encouraging. Tumour and lymph node downstaging was reported in 70.8% and in 67% of patients, respectively, with a pCR (pT0N0) rate of 22%. In addition, the overall tumor pathological complete response (pT0) resulted of 27.8% of cases when all operated patients were considered, including the patients selected for LE (pT0Nx). These results are consistent with pCR rates of 11.5%--19% of the randomised trials, including the INTERACT trial with a pCR and pT0 rates of 23% and 29.8%, respectively (3--7,13). Despite the limitations due to the different RT doses delivered (from 52.5Gy to 57.5Gy, with 2.1Gy--2.3Gy/fraction), our pCR rate of 22% is similar to that reported by other IMRT-SIB intensification series (with doses ranging from 47.5 to 57.5Gy) with a pCR rate of 13--31% \[[@CR24]--[@CR29]\]. Among the studies with a higher rate of pCR, Li et al. \[[@CR25]\] reported a 31% pCR rate with concomitant Capecitabine and an IMRT-SIB dose of 50.6 Gy/23 fractions with a single SIB fraction of 2.3 Gy and Hernando-Requejo et al. \[[@CR26]\] reported similar results (pCR rate of 31%) with Capecitabine and IMRT-SIB dose of 57.5Gy/25 fraction with a single SIB fraction of 2.3 Gy, indicating a possible correlation between dose fraction and response rate, although these data need to be carefully evaluated because of the limited number of treated patients in these series (Table [6](#Tab6){ref-type="table"}). It should be noted that 90% of patients with MRF involvement at diagnosis had negative CRM after CT-RT.

At multivariated analysis, the only parameter which impacted on TRG1 (pT0) and on tumor downstaging rates was the distance of tumor from EAS, wich is a well-known negative prognostic factor, whereas no impact was reported for the other parameters considered in the analysis, including the different dose levels of RT. However, the small number of patients evaluated in each subset considered may have affected this conclusion. Nevetheless, tolerance and response rate in terms of T and N downstaging and TRG appear to indicate the dose range of 52.5--57.5Gy to be effective with IMRT-SIB for LARC. As for postoperative morbidity, we documented a complication rate of 18%. This data is consistent with the 7--23% rate of the other IMRT-SIB studies (Table [6](#Tab6){ref-type="table"}), and appears well comparable with the 25--36% rate reported with 3D--CRT concomitant boost studies \[[@CR11], [@CR13]\]. Interestingly, 8 of 72 (11%) patients underwent LE without significant complications, which suggests the feasibility of organ preservation surgery also after this intensified RT program associated with Capecitabine.

We are aware that our study has several limitations. These include mainly its retrospective nature, the limited number of evaluated patients and the different SIB doses employed due to the different IMRT modalities available at each participating centre. Although patient distribution for the several parameters evaluated at multivariate analysis was quite balanced, the limited sample size might represent a possible explanation for the lack of any significant indication, including the RT dose level. In addition, although all the five participating centres had collaborated on the previous INTERACT rectal cancer trial and shared the same CTVs delineation criteria, the lack of a centralised review of each case could have impacted on the validity of these results. There was also no central review in Mandard TRG scoring. However, even with these limitations, this is to our knowledge the first pooled analysis of a multicentric experience of preoperative IMRT-SIB and full-dose Capecitabine in LARC.

Conclusion {#Sec11}
==========

In conclusion, in our pooled analysis preoperative IMRT-SIB with dose range of 52.5--57.5 Gy (median 54Gy) in 25 fractions and Capecitabine appeared feasible, safe and effective in terms of downstaging and pCR. These short-term results may contribute to the growing evidence of RT intensification in combination with CT as a promising option in the management of LARC. Long-term toxicity and the impact on disease control and patient survival will be evaluated with a longer follow-up time.

The Authors thank Ms. Daniela Michilin, MA, for the manuscript editing.

Funding {#FPar1}
=======

None.

Availability of data and materials {#FPar2}
==================================

The datasets used and analysed during the current study available from the corresponding author on reasonable request.

ML, FM and ADP drafted the manuscript. FM performed clinical data acquisition and analysis.All authors participated in clinical data acquisition at their respective Center. MAG, MO, GM, VV and CA critically revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate {#FPar3}
==========================================

The study was retrospectively approved by the Ethics Committee (Comitato Etico Unico Regionale [www.egas.sanita.fvg.it](http://www.egas.sanita.fvg.it); on April 5, 2017; Ref. n. 9628; study number: CRO-2017-06).

Consent for publication {#FPar4}
=======================

Not applicable.

Competing interests {#FPar5}
===================

The authors declare that they have no competing interests.

Publisher's Note {#FPar6}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
